[Reduction in the need for glucocorticoids on the background of therapy with biologic disease-modifying antirheumatic drugs and Janus kinase inhibitors in rheumatoid arthritis: evidence from real clinical practice].
A S PotapovaA E KarateevE Y PolishchukE S FilatovaV N AmirdzhanovaAlexander M LilaPublished in: Terapevticheskii arkhiv (2024)
Against the background of intensive RA therapy, including combination of DMARDs with bDMARDs or iJAK, complete withdrawal or reduction of GC dose was achieved in less than half (45.6%) of patients after 6 months.
Keyphrases
- rheumatoid arthritis
- disease activity
- end stage renal disease
- clinical practice
- newly diagnosed
- ejection fraction
- rheumatoid arthritis patients
- chronic kidney disease
- ankylosing spondylitis
- interstitial lung disease
- stem cells
- peritoneal dialysis
- patient reported outcomes
- mesenchymal stem cells
- drug induced
- systemic sclerosis
- patient reported